New drug cocktail shows promise for tough gallbladder cancer
NCT ID NCT06591650
First seen May 17, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study tests a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) in people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this mix can shrink tumors and control the disease. About 33 adults who have not had prior treatment will take part. The approach uses chemotherapy to kill cancer cells and an immunotherapy drug to help the immune system fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GALLBLADDER CANCER UNRESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200040, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.